Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. - Wikidata - awgldk - TriplyDB

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

http://www.wikidata.org/entity/Q37473017

about

Raltegravir for the treatment of HIV infection in adults and children Sequencing paediatric antiretroviral therapy in the context of a public health approach Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects Getting to 90-90-90 in paediatric HIV: What is needed?Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093 Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age Paediatric HIV: Progress on Prevention, Treatment and Cure Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.Moving forward with treatment options for HIV-infected children.Challenges and Opportunities in the Development of HIV Medications in Pediatric Patients.Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates.Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational ART.Dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected child.Antiretroviral therapy during the neonatal period.Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.

P2860

Q24186953-260EACDC-A9AC-4EED-A1DE-B806CD0C8698 Q26774261-EB95E662-6955-48AA-BA49-8490FB8B85D8 Q28079594-C95CC5EA-8042-4003-B16A-B00B8339CADC Q30385352-EA9786B2-4C9E-4C87-BBFA-C032C762D8E0 Q36066766-F3085F34-858A-48EF-A06E-78DF78315C68 Q36157266-F415A93C-2C0E-402F-992D-0084BDE5FF72 Q36377397-E3630480-A332-4F8D-A7A0-F725466CB045 Q36395153-AA150C1B-1DA7-4FA5-837C-990429D296A6 Q38166286-0F30024A-0704-49DA-AB10-4E20929F62D6 Q38560855-054A7901-FCC0-41AF-8E17-BD16969FF1B1 Q38910835-6739AC57-9D7F-435D-A158-1D7680FE417C Q40063042-F1B6C005-4B83-49B5-825D-40DC8B3B4005 Q40377157-45BF0DAF-E11F-43B4-A733-9AD5B4AF0716 Q40536799-FEE10FB4-78D3-45BE-8868-3D48F1B342BC Q41728714-387240B0-2F1A-474C-81D6-85BA846900C5 Q42696471-B6243F45-BFEC-4341-BF89-11FC16D659D3 Q45326130-91753CF0-44F8-4E7E-98C7-BFC5ACAD5114 Q49990061-827C11C8-1B58-49B4-BBBD-4ED44DA995EF Q51032691-84F086C5-1D87-47DD-BECF-D53AD41E5F71 Q53801515-2BFD3A43-E5B7-46E0-817D-307FC9E0D33C Q54194778-E19FEEA2-C61B-495A-B681-4C70FD529F02

P2860

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

http://www.wikidata.org/entity/Q37473017

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@en

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@nl

type

label

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@en

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@nl

prefLabel

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@en

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@nl

P1433

Q37473017-21541236-0DC2-4210-BE0B-77EE571CAD22

P1476

Q37473017-AC95B1A8-FEE8-4E16-B990-D1356AE04E4F

P2093

Q37473017-179D1968-E34E-4AE9-87B2-F463C2E1DBB2

Q37473017-2B83E321-C858-48DB-AA82-117E1618F064

Q37473017-32484C2D-31B0-46E8-8E35-97BACF8EDF96

Q37473017-325E3BFA-A526-43CF-9536-486047230A3A

Q37473017-328B4926-3ECC-4787-8A33-7546A81D9D59

Q37473017-5100D441-62F7-47A5-A4B2-C4A91CD5810A

Q37473017-78B257D9-F0B4-474F-840B-3CAC77BFB66E

Q37473017-7AB28DAF-9513-4A40-8EC1-1B9592596452

Q37473017-8002CF0F-89A2-4DFB-92AE-335BE33A9FF6

Q37473017-95943244-9F94-4165-8241-07220277D27B

P2860

Q37473017-1C71A37A-7769-4978-B07A-5E06D69E451F

Q37473017-359BC2D7-C7BA-4159-8F9E-DAD561CA4E1A

Q37473017-4527A005-C988-4F5E-8B21-533FFEBF615B

Q37473017-7DC1F63B-20DA-4F21-92C2-1511DB0DF2A8

Q37473017-8D32125E-37FA-488A-A455-734E83E7D002

Q37473017-A989BD3A-D736-40DB-8FB9-D2E5ADD8544A

Q37473017-B7301303-4BAC-4D09-A045-123EE8F48F7E

Q37473017-CFE02E6B-5469-4E5E-8158-EB65941556E0

P304

Q37473017-6BAE646C-8C69-4C81-A329-045EA22E802C

P31

Q37473017-C095618B-AC87-4463-B0D3-AE11EFFCF146

P356

Q37473017-3AE96397-8F4F-4F5D-87FC-643C7D1FAD67

P407

Q37473017-1D0D6FF0-FCB7-4C68-92F3-696AD942F93E

P433

Q37473017-89E02283-171D-49C1-90C8-DCF0FE5583C3

P478

Q37473017-235E2900-D407-4BD2-932C-7449F934F86C

P50

Q37473017-0C1696D5-4A9D-4DFA-A256-915D496FFD9E

Q37473017-8A65C41A-51DB-461A-902B-D2F4370180EE

P577

Q37473017-2448E538-3AB8-4DB8-BF8C-EBD396125914

P5875

Q37473017-8FBABA5D-2DD2-4035-981A-14689342F11C

P698

Q37473017-F5093358-4D6B-423F-80EE-345CD54CFE60

P921

Q37473017-3160D3A6-8231-4C26-8BE6-A74C31F71735

P932

Q37473017-C9E6527B-288D-4955-B476-4E428F50F98D

P356

P1433

Clinical Infectious Diseases

P1476

Pharmacokinetics, safety, and ...... ldren aged 2 through 18 years.

@en

P2093

Andrew Wiznia

http://www.w3.org/2001/XMLSchema#string

Bobbie Graham

http://www.w3.org/2001/XMLSchema#string

Brenda Homony

http://www.w3.org/2001/XMLSchema#string

Carmelita Alvero

http://www.w3.org/2001/XMLSchema#string

Carol Worrell

http://www.w3.org/2001/XMLSchema#string

Edward Handelsman

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

Hedy Teppler

http://www.w3.org/2001/XMLSchema#string

International Maternal Pediatr ...... als (IMPAACT) P1066 Study Team

http://www.w3.org/2001/XMLSchema#string

Larissa Wenning

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir with optimized background therapy for resistant HIV-1 infection

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.

P304

413-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIT696

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Edward Handelsman

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044921

http://www.w3.org/2001/XMLSchema#string

P698

24145879

http://www.w3.org/2001/XMLSchema#string

P921

P932

3890333

http://www.w3.org/2001/XMLSchema#string